tickrz reports
Thermo Fisher Scientific Inc (TMO)
Healthcare | Health Services
208  -1.03%
TMO vs HEALTH SERVICES SECTOR & S&P 500
VALUATION
TMOSECTORS&P 500
P/E RATIO38.1532.921.12
EV/EBITDA RATIO25.3718.312.66
P/S RATIO4.423.92.25
P/B RATIO3.85.83.45
QUALITY
RETURN ON EQUITY10.16%14.19%13.64%
RETURN ON CAPITAL7.2%20.57%10.09%
NET MARGIN11.08%8.82%9.73%
DIVIDEND ANALYSIS
DIVIDEND YIELD
0.29%
PAYOUT RATIO10.93%
3 YR DIVIDEND GROWTH0%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY78%
INTEREST COVERAGE5.6x
CURRENT RATIO1.37
GROWTH
5 YR EPS GROWTH13.82%
5 YR SPS GROWTH9.59%
5 YR BPS GROWTH6.22%
Thermo Fisher Scientific Inc News
At $210.17, Is Thermo Fisher Scientific Inc (NYSE:TMO) A Buy?
Thermo Fisher Scientific Inc (NYSE:TMO) saw a decent share price growth in the teens level on the NYSE over the last few months. With many analysts covering the large-cap stock,Read More...
January 16, 21:24:19 UTC

What Are Accelerate Diagnostics’ Key Strengths?
How Is Accelerate Diagnostics Positioned at the Start of 2018? In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock. As a result of the offering, the cash position of the company increased to $121.3 million at the end of 3Q17 as compared with $77.8 million at the end of 3Q16.
January 15, 14:02:29 UTC

Illumina (ILMN) Ties Up With Thermo Fisher for Ion AmpliSeq
Illumina (ILMN) consistently tries to enhance NGS platform.
January 15, 13:30:01 UTC

See what the IHS Markit Score report has to say about Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc NYSE:TMO
January 15, 13:06:13 UTC

Does Accelerate Diagnostics’ Financial Performance Bode Well?
How Is Accelerate Diagnostics Positioned at the Start of 2018? The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17. For fiscal 2017, Accelerate Diagnostics is expected to report revenues of $5 million, while peers Becton Dickinson (BDX), Bruker (BRKR), and Thermo Fisher Scientific (TMO) are expected to report revenues of $12 billion, $1.7 billion, and $20.5 billion, respectively.
January 15, 12:33:49 UTC

3 Stocks for Retirees to Grow Their Nest Egg
Welltower, Sherwin Williams, and Thermo Fischer Scientific could make great buys for retirees today.
January 13, 16:03:00 UTC

What’s the Competitive Landscape for Accelerate Diagnostics?
How Is Accelerate Diagnostics Positioned at the Start of 2018?
January 12, 17:20:02 UTC

What Analysts Recommend for Accelerate Diagnostics and Peers
Tuscon-based Accelerate Diagnostics (AXDX) is a diagnostics company focused on developing solutions and tools to provide rapid diagnostic results. While results from traditional culture-based tests usually take two to three days, Accelerate’s technology platform is built to deliver substantially faster and more accurate testing of infectious pathogens. The platform is intended to rapidly diagnose infectious pathogens.
January 12, 14:18:54 UTC

Alamo Group, Inc. (ALG) Ex-Dividend Date Scheduled for January 12, 2018
Alamo Group Inc ALG will begin trading ex dividend on January 12 2018 A cash dividend payment of 0 11 per share is scheduled to be paid on January 29 2018 Shareholders who purchased ALG prior to the ex dividend date are eligible for the cash dividend payment This represents an
January 11, 14:13:52 UTC

Stryker Stock: Wall Street Recommendations and Target Price
Stryker's 52-Week High: Should You Expect Further Upside?
January 10, 20:35:03 UTC

Pacific Biosciences Hurt by Competition in Niche Markets
On Jan 9 we issued an updated research report on Pacific Biosciences of California Inc PACB Solid contribution from the Instrument and Consumable revenue platforms have been boosting Pacific Biosciences growth trajectory However cutthroat competition in the niche space has been
January 10, 17:13:21 UTC

Baxter International Expected to Post Strong 4Q17 Results
Baxter Reaches 52-Week High: What's behind the Stock Rally?
January 10, 15:33:41 UTC

Thermo Fisher Scientific Hits 80-Plus Relative Strength Rating Benchmark
Thermo Fisher Scientific shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.
January 10, 08:00:00 UTC

5 Reasons Illumina Enjoyed a Big J.P. Morgan Conference Bounce
Illumina NASDAQ ILMN CEO Francis deSouza spoke at the J P Morgan Healthcare Conference in San Francisco on Monday after the market closed You only have to look at how the gene sequencing leader s stock performed on Tuesday to know how his presentation was received Illumina
January 09, 22:07:48 UTC

Baxter International’s Profit Margins Expected to Expand
Baxter Reaches 52-Week High: What's behind the Stock Rally?
January 09, 21:00:02 UTC


Thermo Fisher Scientific Inc (TMO)
Healthcare | Health Services
208  -1.03%

At $210.17, Is Thermo Fisher Scientific Inc (NYSE:TMO) A Buy?
Thermo Fisher Scientific Inc (NYSE:TMO) saw a decent share price growth in the teens level on the NYSE over the last few months. With many analysts covering the large-cap stock,Read More...
January 16, 21:24:19 UTC

What Are Accelerate Diagnostics’ Key Strengths?
How Is Accelerate Diagnostics Positioned at the Start of 2018? In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock. As a result of the offering, the cash position of the company increased to $121.3 million at the end of 3Q17 as compared with $77.8 million at the end of 3Q16.
January 15, 14:02:29 UTC

Illumina (ILMN) Ties Up With Thermo Fisher for Ion AmpliSeq
Illumina (ILMN) consistently tries to enhance NGS platform.
January 15, 13:30:01 UTC

See what the IHS Markit Score report has to say about Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc NYSE:TMO
January 15, 13:06:13 UTC

Does Accelerate Diagnostics’ Financial Performance Bode Well?
How Is Accelerate Diagnostics Positioned at the Start of 2018? The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17. For fiscal 2017, Accelerate Diagnostics is expected to report revenues of $5 million, while peers Becton Dickinson (BDX), Bruker (BRKR), and Thermo Fisher Scientific (TMO) are expected to report revenues of $12 billion, $1.7 billion, and $20.5 billion, respectively.
January 15, 12:33:49 UTC

3 Stocks for Retirees to Grow Their Nest Egg
Welltower, Sherwin Williams, and Thermo Fischer Scientific could make great buys for retirees today.
January 13, 16:03:00 UTC

What’s the Competitive Landscape for Accelerate Diagnostics?
How Is Accelerate Diagnostics Positioned at the Start of 2018?
January 12, 17:20:02 UTC

What Analysts Recommend for Accelerate Diagnostics and Peers
Tuscon-based Accelerate Diagnostics (AXDX) is a diagnostics company focused on developing solutions and tools to provide rapid diagnostic results. While results from traditional culture-based tests usually take two to three days, Accelerate’s technology platform is built to deliver substantially faster and more accurate testing of infectious pathogens. The platform is intended to rapidly diagnose infectious pathogens.
January 12, 14:18:54 UTC

Alamo Group, Inc. (ALG) Ex-Dividend Date Scheduled for January 12, 2018
Alamo Group Inc ALG will begin trading ex dividend on January 12 2018 A cash dividend payment of 0 11 per share is scheduled to be paid on January 29 2018 Shareholders who purchased ALG prior to the ex dividend date are eligible for the cash dividend payment This represents an
January 11, 14:13:52 UTC

Stryker Stock: Wall Street Recommendations and Target Price
Stryker's 52-Week High: Should You Expect Further Upside?
January 10, 20:35:03 UTC

Pacific Biosciences Hurt by Competition in Niche Markets
On Jan 9 we issued an updated research report on Pacific Biosciences of California Inc PACB Solid contribution from the Instrument and Consumable revenue platforms have been boosting Pacific Biosciences growth trajectory However cutthroat competition in the niche space has been
January 10, 17:13:21 UTC

Baxter International Expected to Post Strong 4Q17 Results
Baxter Reaches 52-Week High: What's behind the Stock Rally?
January 10, 15:33:41 UTC

Thermo Fisher Scientific Hits 80-Plus Relative Strength Rating Benchmark
Thermo Fisher Scientific shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.
January 10, 08:00:00 UTC

5 Reasons Illumina Enjoyed a Big J.P. Morgan Conference Bounce
Illumina NASDAQ ILMN CEO Francis deSouza spoke at the J P Morgan Healthcare Conference in San Francisco on Monday after the market closed You only have to look at how the gene sequencing leader s stock performed on Tuesday to know how his presentation was received Illumina
January 09, 22:07:48 UTC

Baxter International’s Profit Margins Expected to Expand
Baxter Reaches 52-Week High: What's behind the Stock Rally?
January 09, 21:00:02 UTC